Safety of bivalirudin in patients with coronary artery disease

Bibliography

• Wijns W, Kolh P, Danchin N, Guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31:2501-55
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008;99:830
   PubMed Web of Science ®Google Scholar
• The Medicines Co. Angiomax (package insert). BenVenue Laboratories; Bedford, OH: 2005
   Google Scholar
• Ahrens I, Smith BK, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology. Expert Opin Drug Metab Toxicol 2007;3:609-20
   PubMed Web of Science ®Google Scholar
• Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12(Suppl F):27F-32
   PubMedGoogle Scholar
• Witting JI, Bourdon P, Brezniak DV, Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992;283:737-43
   PubMed Web of Science ®Google Scholar
• Robson RA. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12:F33-6
   PubMedGoogle Scholar
• Maraganore JM, Adelman BA. Hirulog: a direct thrombin inhibitor for management of acute coronary syndromes. Coron Artery Dis 1996;7:438-4
   PubMed Web of Science ®Google Scholar
• Lui HK. Dosage, pharmacological effects and clinical outcomes for bivalirudin in percutaneous coronary intervention. J Invasive Cardiol 2000;12(Suppl F):41F-52
   PubMedGoogle Scholar
• Topol EJ, Bonan R, Jewitt D, Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-9
   PubMed Web of Science ®Google Scholar
• Bittl JA, Strony J, Brinker JA, Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-9
   PubMed Web of Science ®Google Scholar
• Bittl JA, Chaitman BR, Feit F, Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Kleiman NS, Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc 2003;289:853-63
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Bittl JA, Kleiman NS, For the REPLACE-1 investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduce Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004;93:1092-6
   PubMed Web of Science ®Google Scholar
• Saw J, Lincoff AM, DeSmet W, Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade. A REPLACE-2 substudy. J Am Coll Cardiol 2004;44:1194-9
   PubMed Web of Science ®Google Scholar
• Lincoff AM, Kleiman NS, Kereiakes DJ, For the REPLACE-2 investigators. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization. J Am Med Assoc 2004;292:696-703
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Koster A. Bivalirudin: a review. Expert Opin Pharmacother 2005;6:1349-71
   PubMed Web of Science ®Google Scholar
• Kastrati A, Neumann FJ, Mehilli J, ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96
   PubMed Web of Science ®Google Scholar
• Iijima R, Ndrepepa G, Mehilli J, Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 2009;30:290-6
   PubMed Web of Science ®Google Scholar
• Stone GW, McLaurin BT, Cox DA, Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30
   PubMed Web of Science ®Google Scholar
• Mehran R, Lansky AJ, Witzenbichler B, HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 2009;374:1149-59
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Guagliumi G, HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204
   PubMed Web of Science ®Google Scholar
• De Luca G, Cassetti E, Verdoia M, Marino P. Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty. A meta-analyis of randomised trials. Thromb Haemost 2009;102:428-36
   PubMed Web of Science ®Google Scholar
• Dangas GD, Caixeta A, Mehran R, For the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011;123:1745-56
   PubMed Web of Science ®Google Scholar
• Raber L, Windecker S. Primary percutaneous coronary intervention and risk of stent thrombosis: a look beyond the HORIZON. Circulation 2011;123:1709-12
   PubMed Web of Science ®Google Scholar
• Anderson PR, Gogo PB, Ahmed B, Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction. J Thromb Thrombolysis 2011;31:401-6
   PubMed Web of Science ®Google Scholar
• Doll JA, Nikolsky E, Stone GW, Outcomes of patients with coronary artery perforation complicating percutaneous coronary intervention and correlations with the type of adjunctive antithrombotic therapy: pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials. J Interv Cardiol 2009;22:453-9
   PubMed Web of Science ®Google Scholar
• Kini AS, Rafael OC, Sarkar K, Changing outcomes and treatment strategies for wire induced coronary perforations in the era of bivalirudin use. Catheter Cardiovasc Interv 2009;74:700-7
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Yang Q, Pieper KS, Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med 2008;23:310-16
   PubMed Web of Science ®Google Scholar
• Bassand JP, Hamm CW, Ardissino D, Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
   PubMed Web of Science ®Google Scholar
• Dangas GD, Mehran R, Nikolsky E, HORIZONS-AMI trial investigators. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction. The HORIZONS-SWITCH Analysis. J Am Coll Cardiol 2011;57:2309-16
   PubMed Web of Science ®Google Scholar
• White HD, Chew DP, Hoekstra JW, Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008;51:1734-41
   PubMed Web of Science ®Google Scholar
• Waksman R, Wolfram RM, Torguson RL, Switching from enoxaparin to bivalirudin in patients with acute coronary syndromes without ST-segment elevation who undergo percutaneous coronary intervention. Results from SWITCH – a multicenter clinical trial. J Invasive Cardiol 2006;18:370-5
   PubMedGoogle Scholar
• Hamon M, Rasmussen LH, Manoukian SV, Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention 2009;5:115-20
   PubMed Web of Science ®Google Scholar
• Lopes RD, Alexander KP, Manoukian SV, Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009;53:1021-30
   PubMed Web of Science ®Google Scholar
• Khattab AA, Ndrepepa G, Schulz S, Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial. Clin Res Cardiol 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Rassen JA, Mittleman MA, Glynn RJ, Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J 2010;31:561-72
   PubMed Web of Science ®Google Scholar
• Di Nisio M, Middeldorp S, Buller HR.Direct thrombin inhibitors. N Engl J Med 2005;353:1028-40
   PubMed Web of Science ®Google Scholar